Dataset Information

Expression of the epidermal growth factor receptor gene is regulated in mouse blastocysts during delayed implantation.

ABSTRACT: The delayed implantation model was used to study epidermal growth factor receptor(s) (EGF-R) in the mouse blastocyst. Delayed implantation and blastocyst dormancy were induced by ovariectomy on day 4 of pregnancy and were maintained by daily (days 5-7) injections of progesterone (P4). Blastocyst activation and implantation were initiated by coinjection of estradiol-17 beta (E2) with P4 on the 3rd day of delay. Immunostaining of EGF-R, autoradiographic detection of 125I-labeled EGF binding, and measurement of EGF-inducible subcellular protein tyrosine phosphorylation demonstrated the loss of EGF-R from blastocysts (dormant) recovered 24 h after ovariectomy or on the 3rd day of P4-maintained delay. However, increased EGF-R levels were detected in blastocysts (activated) recovered 12 or 24 h after E2 injection. Blastocyst EGF-R mRNA levels were quantitated by reverse transcriptase (RT)-PCR and distribution of this mRNA was examined by in situ hybridization. To provide a homologous probe for these studies, a mouse EGF-R partial cDNA was cloned and used as the template for synthesis of antisense- and sense-strand EGF-R RNA. Quantitative RT-PCR demonstrated an 8- to 10-fold reduction in EGF-R mRNA copies per cell in dormant blastocysts. In contrast, an 8-fold increase in EGF-R mRNA copies per cell was detected in activated blastocysts 8 h after injection of E2. In situ hybridization detected EGF-R mRNA in most cells of normal day 4 blastocysts but not in those of dormant blastocysts. These studies establish that expression of the EGF-R gene in mouse blastocysts is tightly regulated by maternal steroid hormonal status.

SUBMITTER: Paria BC

PROVIDER: S-EPMC45598 | biostudies-other | 1993 Jan

REPOSITORIES: biostudies-other

ACCESS DATA

Publications

Expression of the epidermal growth factor receptor gene is regulated in mouse blastocysts during delayed implantation.

Paria B C BC Das S K SK Andrews G K GK Dey S K SK

Proceedings of the National Academy of Sciences of the United States of America 19930101 1

The delayed implantation model was used to study epidermal growth factor receptor(s) (EGF-R) in the mouse blastocyst. Delayed implantation and blastocyst dormancy were induced by ovariectomy on day 4 of pregnancy and were maintained by daily (days 5-7) injections of progesterone (P4). Blastocyst activation and implantation were initiated by coinjection of estradiol-17 beta (E2) with P4 on the 3rd day of delay. Immunostaining of EGF-R, autoradiographic detection of 125I-labeled EGF binding, and m ...[more]

PMID: 7678348

Similar Datasets

Project description:PurposeSubset analyses from phase III evaluation of epidermal growth factor receptor inhibition (EGFRi) suggest improved outcomes in patients with EGFR-amplified gastroesophageal adenocarcinoma (GEA), but large-scale analyses are lacking. This multi-institutional analysis sought to determine the role of EGFRi in the largest cohort of patients with EGFR-amplified GEA to date.Patients and methodsA total of 60 patients from 15 tertiary cancer centers in six countries met the inclusion criteria. These criteria required histologically confirmed GEA in the metastatic or unresectable setting with EGFR amplification identified by using a Clinical Laboratory Improvement Amendments-approved assay, and who received on- or off-protocol EGFRi. Testing could be by tissue next-generation sequencing, plasma circulating tumor DNA next-generation sequencing, and/or fluorescence in situ hybridization performed by a Clinical Laboratory Improvement Amendments approved laboratory. Treatment patterns and outcomes analysis was also performed using a deidentified clinicogenomic database (CGDB).ResultsSixty patients with EGFR-amplified GEA received EGFRi, including 31 of 60 patients (52%) with concurrent chemotherapy. Across treatment lines, patients achieved a 43% objective response rate with a median progression-free survival of 4.6 months (95% CI, 3.5 to 6.4). Patients receiving EGFRi in first-, second-, and third-line therapy achieved a median overall survival of 20.6 months (95% CI, 13.5 to not reached [NR]), 9 months (95% CI, 7.9 to NR), and 8.4 months (7.6 to NR), respectively. This survival far exceeded the 11.2-month (95% CI, 8.7 to 14.2) median overall survival from first-line initiation of non-EGFRi therapy in patients with EGFR-amplified GEA in the CGDB. Despite this benefit, analysis of the CGDB (January 2011-December 2020) suggests that only 5% of patients with EGFR-amplified GEA received EGFRi.ConclusionPatients with EGFR-amplified GEA derive significant benefit from EGFRi. Further prospective investigation of EGFRi in a well-selected patient population is ongoing in an upcoming trial of amivantamab in EGFR and/or MET amplified GEA.

Project description:Infertility and adverse gynecological outcomes such as preeclampsia and miscarriage represent significant female reproductive health concerns. The spatiotemporal expression of growth factors indicates that they play an important role in pregnancy. The goal of this study is to define the role of the ERBB family of growth factor receptors in endometrial function. Using conditional ablation in mice and siRNA in primary human endometrial stromal cells, we identified the epidermal growth factor receptor (Egfr) to be critical for endometrial function during early pregnancy. While ablation of Her2 or Erbb3 led to only a modest reduction in litter size, mice lacking Egfr expression are severely subfertile. Pregnancy demise occurred shortly after blastocyst implantation due to defects in decidualization including decreased proliferation, cell survival, differentiation and target gene expression. To place Egfr in a genetic regulatory hierarchy, transcriptome analyses was used to compare the gene signatures from mice with conditional ablation of Egfr, wingless-related MMTV integration site 4 (Wnt4) or boneless morphogenic protein 2 (Bmp2); revealing that not only are Bmp2 and Wnt4 key downstream effectors of Egfr, but they also regulate distinct physiological functions. In primary human endometrial stromal cells, marker gene expression, a novel high content image-based approach and phosphokinase array analysis were used to demonstrate that EGFR is a critical regulator of human decidualization. Furthermore, inhibition of EGFR signaling intermediaries WNK1 and AKT1S1, members identified in the kinase array and previously unreported to play a role in the endometrium, also attenuate decidualization. These results demonstrate that EGFR plays an integral role in establishing the cellular context necessary for successful pregnancy via the activation of intricate signaling and transcriptional networks, thereby providing valuable insight into potential therapeutic targets.

Dataset Information

Expression of the epidermal growth factor receptor gene is regulated in mouse blastocysts during delayed implantation.

Publications

Expression of the epidermal growth factor receptor gene is regulated in mouse blastocysts during delayed implantation.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets